bioRxiv · 10.1101/2025.06.13.659577
Modulation of SLP-2 expression protects against alpha-synuclein neuropathology by mitigating mitochondrial dysfunction
Abstract
Parkinsons Disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss and the accumulation of alpha-synuclein (Syn)-rich aggregates known as Lewy bodies. Mitochondrial dysfunction is a key contributor to PD pathology, and mitochondrial defects are part of the pathogenic mechanisms induced by Syn. Stomatin-Like protein 2 (SLP-2) is a mitochondrial scaffold protein that regulates mitochondrial integrity and function. Here, we investigated whether SLP-2 induction can counteract Syn-induced mitochondrial dysfunction and neurodegeneration. We found that SLP-2 levels were reduced in human PD brains and an A53T Syn mouse model. Mild overexpression of SLP-2 improved mitochondrial function, reduced oxidative stress, and prevented Syn-mitochondria interactions in human iPSC-derived neurons. In vivo, SLP-2 overexpression protected dopaminergic neurons and motor function, while its depletion exacerbated degeneration and motor deficits in both mouse and Drosophila models. These findings suggest SLP-2 as a key regulator of mitochondrial resilience and a potential therapeutic target for PD and alpha-synucleinopathies.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Bolduc, C., Castelo Rueda, M. P., Lorente Picon, M., Gentile, G., Kalvakuri, S., Soto Linan, V., Zanon, A., Laouafa, S., Lang, M., Lavdas, A. A., Gilmozzi, V., Bernardo, G., Coulombe, V., Gora, C., Peralta, M., Rioux, V., Honisch, C., Pramstaller, P. P., Ruzza, P., Ziviani, E., Bodmer, R., Hicks, A. A., Parent, M., Soliz, J., Joseph, V., Pichler, I., Levesque, M.. 2025-06-15. Modulation of SLP-2 expression protects against alpha-synuclein neuropathology by mitigating mitochondrial dysfunction. https://doi.org/10.1101/2025.06.13.659577
Cite the original work for its findings. Save a collection to share your selection of sources.